- Home
- Solutions
- By Diseases
- Autoimmune Ophthalmic Diseases
- Blepharitis
Blepharitis is a common condition, without geographical or temporal limitations, characterized by persistent inflammation of eyelid borders. Protheragen leads the market in the development of diagnostics and therapeutics for blepharitis. Our wide array of services, balanced with our unwavering standards of scientific rigor and ethics, allows us to maintain an advanced position within the industry of therapeutics for blepharitis.
Blepharitis occurs when inflammation affects the eyelid margins and can happen to people of all ages. It is marked by burning sensations, itching, tearing, increased sensitivity to light, and eye redness. This condition can be divided into two categories: anterior blepharitis which affects eyelashes and follicles, and posterior blepharitis which is associated with the dysfunction of meibomian glands. Oftentimes, it is associated with systemic diseases such as rosacea, seborrheic dermatitis, dry eyes, and keratitis. Even though it is common, blepharitis pathophysiology is complicated and is the result of microbial colonization, tear film imbalance, and immune response.
Fig.1 Analysis of symptoms of blepharitis. (Di Zazzo A., et al., 2024)
| Therapeutics | Target | Description | Stage |
| Topical Antibiotics | Bacterial Infections | Erythromycin and bacitracin ointments are commonly used to treat bacterial blepharitis. | Approved |
| Topical Corticosteroids | Inflammation | Used in severe cases to reduce inflammation. Typically administered with a tapering course to avoid complications. | Approved |
| Systemic Antibiotics | Severe/Chronic Blepharitis | Doxycycline and azithromycin are prescribed for severe or chronic cases to reduce bacterial colonization and inflammation. | Approved |
| Omega-3 Supplements | Meibomian Gland Dysfunction | Improve meibomian gland function and reduce inflammation in posterior blepharitis. | Approved |
| Topical Cyclosporin A | Inflammation | Reduces inflammation and meibomian gland inclusions, particularly in refractory cases. | Approved |
| Artificial Tears | Dry Eye Symptoms | Used to manage dry eye symptoms associated with blepharitis, improving tear film function. | Approved |
| Bortezomib | Multiple Myeloma | A proteasome inhibitor associated with blepharitis as a side effect. Management involves conservative measures and potential discontinuation. | Approved |
| Cetuximab | Colorectal Cancer | A monoclonal antibody causes blepharitis as an ocular side effect. Management includes conservative measures and potential discontinuation. | Approved |
| TNF-α Inhibitors | Autoimmune Disorders | Infliximab and adalimumab are associated with blepharitis. Management involves conservative measures and potential discontinuation. | Approved |
| Dupilumab | Atopic Dermatitis, Asthma | A monoclonal antibody linked to ocular surface disease, including blepharitis. Management includes local steroids and potential discontinuation. | Approved |
Disclaimer: Protheragen focuses on providing preclinical research service. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Protheragen provides extensive services for the development of diagnostic and therapeutic solutions for blepharitis. Our expertise lies in creating targeted therapeutics, such as topical and systemic antibiotics, corticosteroids, omega-3 supplements, and immunomodulatory agents.
At Protheragen, our preclinical research services are specifically designed to advance the development of innovative therapeutics for blepharitis. Leveraging our cutting-edge facilities and highly skilled team, we perform thorough preclinical studies to meticulously assess the efficacy and safety of emerging therapeutic candidates. If you are interested in our services, please feel free to contact us.
References
Copyright © Protheragen. All rights reserved.
